due to major impact on activities of daily living, and thus, early use of csDMARD therapy is encouraged. The limited available evidence supports the use of methotrexate Biologic DMARDs Biologic DMARDs are conditionally recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active TMJ arthritis. There is no preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and